Shots:
- Corcept has submitted NDA of relacorilant to the US FDA for the treatment of endogenous hypercortisolism (Cushing’s syndrome)
- Submission was based on pivotal GRACE study, confirmatory P-III (GRADIENT) & long-term extension trials plus P-II hypercortisolism trial. Relacorilant showed improved symptoms without adrenal insufficiency, hypokalemia, QT prolongation, or progesterone receptor-related AEs (endometrial thickening or vaginal bleeding)
- Relacorilant is a selective cortisol modulator that targets the glucocorticoid receptor. It is also being studied for cancers like ovarian, adrenal & prostate other than hypercortisolism
Ref: Corcept Therapeutics | Image: Corcept Therapeutics
Related News:- Corcept Concludes Patient Recruitment in the P-II Study of Dazucorilant for Amyotrophic Lateral Sclerosis (ALS)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
